Prostate-specific antigen (PSA) has been used as a tumor marker for many years; however, the US Preventive Services Task Force (USPSTF) recommends against any routine PSA-based screening for prostate cancer [4]. The gene discussed is KLK3; the disease is prostate carcinoma.